ProFactor Pharma

Transforming treatment availability for Haemophilia A

ProFactor Pharma Ltd (PFP) is developing factor VIII (FVIII) for the treatment of Haemophilia A. 

Our business is to manufacture low cost recombinant FVIII to a severely undersupplied world market.

PFP licenses FVIII technology to PT Bio Farma (Persero) of Indonesia for potential $1.36bn ASEAN-6 & India territories

Learn More

According to the World Health Organisation (WHO) and the World Federation of Hemophilia around two thirds of the haemophilia patient population receive inadequate or no treatment at all.

Recent News

World Hemophilia Day

The World Federation of Hemophilia (WFH) have set April 17, 2023 as World Hemophilia Day. The theme of the event this year is “Access for All: Prevention of bleeds as the global standard of care”. Building on last year’s theme, the call to action for the community in...

read more